ClinicalTrials.gg
CompletedNCT02183623Updated Jul 8, 2014

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

A Phase 1 interventional study of Simvastatin and 10 mg BI 1356 BS in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
Male
01

Study summary

Investigation of the multiple dose pharmacokinetics, safety and tolerability of simvastatin and simvastatin acid with and without concomitant administration of BI 1356 BS

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the following criteria: No findings deviating from normal and of clinical relevance as well as no evidence of a concomitant disease based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), clinical laboratory tests
  • Age ≥21 and Age ≤65 years
  • ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or-neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs, including herbal products, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of study centre
  • Not willing to use adequate (condom use plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole study period from the time of the first intake of study drug until one month after the last intake
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BI 1356 BS and Simvastatin

    Drug: Simvastatin · Drug: 10 mg BI 1356 BS

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of simvastatin in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 600 hours after first administration

  2. Cmax,ss (maximum measured concentration of simvastatin in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 600 hours after first administration

Secondary outcomes

  1. Tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)

    Time frame: up to 600 hours after first administration

  2. Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 600 hours after first administration

  3. Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)

    Time frame: up to 600 hours after first administration

  4. λz,ss (terminal rate constant in plasma at steady state)

    Time frame: up to 600 hours after first administration

  5. t1/2,ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: up to 600 hours after first administration

  6. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)

    Time frame: up to 600 hours after first administration

  7. CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)

    Time frame: up to 600 hours after first administration

  8. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)

    Time frame: up to 600 hours after first administration

  9. AUCτ,ss (area under the concentration-time curve of simvastatin acid and BI 1356 BS in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 600 hours after first administration

  10. Cmax,ss (maximum measured concentration of simvastatin acid and BI 1356 BS in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 600 hours after first administration

  11. Number of patients with adverse events

    Time frame: up to day 30

  12. Clinically relevant changes in clinical laboratory values

    Time frame: up to day 30

  13. Assessment of tolerability by investigator on a 4-point scale

    Time frame: up to day 30

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 8, 2014
Start
Sep 2005
Primary completionActual
Oct 2005
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183623
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Sep 2005
Primary completion
Oct 2005
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion